https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD. A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi meth
Like
Comment
Share
